Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04398537
Other study ID # R20-040
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 3, 2020
Est. completion date July 26, 2023

Study information

Verified date December 2023
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a single-center prospective randomized control trial that is Institutional Review Board (IRB) approved. The study plans to enroll 250 female patients presenting to the University of Alabama at Birmingham (UAB) for stereotactic biopsy. This study is a prospective and will target approximately 250 patients. This will be a HIPPA-compliant randomized control trial planned on spanning approximately six months' time. Patients will be entered into the study only based on their already scheduled stereotactic biopsy procedure. Patients will be informed of the study and they will be offered the opportunity to participate or not participate in the study. Their participation is completely voluntary. This study will not involve any intervention that is not already a part of standard care. Patients will be randomized to two groups, one group that will undergo clip placement with approximately with a 5 mm retraction of the biopsy clip post-placement and one that will involve no retraction prior to deployment.


Recruitment information / eligibility

Status Completed
Enrollment 245
Est. completion date July 26, 2023
Est. primary completion date January 14, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Females 18-99 of age with recommendation for stereotactic biopsy. Exclusion Criteria: - Non-female patients - Patients < 18 years old - Women who are pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Device:
5mm retraction of clip deployment apparatus.
Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
No retraction of clip deployment apparatus.
This is one method of standard of care and the clip will be deployed at the biopsy site.

Locations

Country Name City State
United States The University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Breast Biopsy Patients Whose Clip Migrated Greater Than 10mm From the Biopsy Site. This number of participants will be counted if their clip migrated more than 10mm from the biopsy site. baseline through 1 hour (post biopsy mammogram/procedure)
Primary Percentage of Breast Biopsy Patients Whose Clip Migrated Greater Than 10mm From the Biopsy Site. baseline through 1 hour (post biopsy mammogram/procedure)
Primary Average Distance of Clip Migration for the Arm That Received 5mm Retraction. baseline through 1 hour (post biopsy mammogram/procedure)
Primary Average Distance of Clip Migration for the Arm That Did Not Receive Clip Retraction. baseline through 1 hour (post biopsy mammogram/procedure)
See also
  Status Clinical Trial Phase
Completed NCT06371989 - Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders After Neoadjuvant Therapy: BISUCO TRIAL N/A
Completed NCT03212040 - 14 g vs. 16 g in Breast Biopsy N/A
Recruiting NCT03842358 - Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography N/A